All News

Taking effect in October 2026, the final rule will end federal Medicaid and CHIP funding for gender-affirming care for transgender minors.

A new international platform trial groups rare pediatric sarcoma substudies under 1 protocol to speed drug access and data collection.

Trump's vaccine executive order calls for fewer routine childhood vaccines and changes to MMR, raising questions about coverage, access, and vaccine uptake.

Most Medicare beneficiaries with ATTR-CM waited more than 6 months for diagnosis after heart failure onset, with longer delays among women.

HHS announced proposed FDA changes to GRAS oversight and a proposed definition of ultra-processed foods as part of the MAHA agenda.

The BTK inhibitor also showed fewer severe adverse events and better patient-reported quality of life than chemoimmunotherapy.

Obesity may independently worsen psoriasis severity and blunt response to fixed-dose biologics, prompting calls for weight-adapted treatment selection.

Extreme heat may accelerate plastic breakdown and increase microplastic exposure, with potential CV, endocrine, and skin health effects, said Eva R. Parker, MD.

Bipartisan Senate bill would codify 340B patient rules, end rebate model, boost oversight—as CMS separately proposes deep Medicare 340B payment cuts.

Brittany G. Craiglow, MD, FAAD, discusses JAK inhibitor hesitancy in pediatric alopecia areata, boxed warnings, and why step therapy falls short.

Arshad Khanani, MD, explains why gene therapy for wet age-related macular degeneration (AMD) is close to becoming a real-world option for the masses.

Although new guidelines call for universal screening, most Americans with elevated Lp(a) still don't know their number.

A large UK cohort study found atopic dermatitis raises the risk of shingles by 28%, with the steepest risk in severe disease and younger adults.

A new $20 billion national strategy targets long-standing gaps in women's health research, care, and funding.

July AJMC author Anuraag R. Kansal, PhD, explains how metastatic cancer diagnoses drive Medicaid spending and why earlier screening could lower costs.

New smartwatch data show women's nighttime awakenings jump sharply at midlife—far more than men's—hinting at a menopause-linked sleep shift.

The FDA approved Viatris' Gwyn Lo, a once-weekly low-dose estrogen (20 mcg) contraceptive patch, based on phase 3 LUMINOUS data showing a Pearl Index of 4.14 pregnancies per 100 woman-years and strong adhesion (98.7% intact). It's approved for women with BMI under 30; common side effects included application-site irritation and intercycle bleeding. Available later in 2026.

Global third-dose hepatitis B (HepB3) vaccine coverage reached 81.8% in 2023, but persistent gaps in Africa and South Asia threaten WHO elimination goals.

The OVERLORD-MS trial finds rituximab matches ocrelizumab in relapsing multiple sclerosis, with similar MRI control, relapses, and safety.

Experts at the Washington, DC, Pop Health Roundtable discussed delays in ILD diagnosis, multidisciplinary care, antifibrotic therapy, and insurance barriers.

All from July, these 5 novel therapeutics each claimed a “first” in their category.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Phase 3 SOLARIS found high-dose vitamin D3 added to standard chemotherapy did not significantly improve progression-free survival in metastatic CRC.

A new AHA scientific statement defines pediatric cardiogenic shock and proposes a 5-stage classification to guide diagnosis, monitoring, and escalation of care.

MASLD was linked to higher odds of EoE and reflux-related diseases, suggesting metabolic dysfunction may contribute to esophageal disease.

Moderna’s mRNA flu vaccine receives FDA approval after phase 3 data showed improved efficacy compared with standard flu vaccines.

CANN says the revised pilot reflects stakeholder input and aims to address accountability challenges in the more than $100 billion 340B program.

Higher CCI scores, prior infection, and prior prophylactic anti-infective treatment were associated with greater risk of subsequent infection in both cancers.